Palvella Therapeutics (PVLA) Total Debt (2013 - 2014)
Palvella Therapeutics' (PVLA) quarterly Total Debt came in at $1.3 million in Q4 2014, down 23.08% year-on-year from $1.7 million in Q4 2013, and up 32083.51% on a QoQ basis from $3948.0 in Q3 2014.
Palvella Therapeutics (PVLA) Total Debt (2013 - 2014) Analysis & Trends
Palvella Therapeutics (PVLA) has 2 years of Total Debt data on file, last reported at $1.3 million in Q4 2014.
- On a quarterly basis, Total Debt fell 23.08% year-over-year to $1.3 million in Q4 2014; TTM through Dec 2014 was $1.3 million, a 23.08% decrease from a year earlier, with the FY2014 full-year figure at $1.3 million, down 23.08% from the prior year.
- Total Debt for Q4 2014 stood at $1.3 million, up from $3948.0 in the prior quarter.
- Over the last five years, Total Debt for PVLA reached as high as $1.7 million in Q4 2013 and fell as low as $474.0 in Q2 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 110.96 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 959.06 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 1.99 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Palvella Therapeutics | 1.84 Bn | 1.57 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2014 | 1.27 Mn |
| Sep 30, 2014 | 3,948.00 |
| Jun 30, 2014 | 948.00 |
| Mar 31, 2014 | 2,474.00 |
| Dec 31, 2013 | 1.65 Mn |
| Jun 30, 2013 | 474.00 |